Drug-induced lupus erythematosus secondary to nafcillin: the first reported case.
With an estimated incidence of 15-30,000 cases per year in the United States, drug-induced lupus erythematosus (DIL) is an uncommon iatrogenic condition. The number of implicated medications increases each year. We report the first case of DIL secondary to nafcillin administration in a patient with a prosthetic aortic valve and methicillin-sensitive Staphylococcus aureus who developed a facial rash and lower back pain.
Blazes
David L
DL
Infectious Diseases Service, National Naval Medical Center, 8901 Wisconsin Avenue, Bethesda, Maryland 20889, USA. DLBlazes@bethesda.med.navy.mil
Martin
Gregory J
GJ
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009254:Nafcillin / Q000009:adverse effects*; D013207:Staphylococcal Skin Infections / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D013211:Staphylococcus aureus / Q000302:isolation & purification; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D009254:Nafcillin